Please assess the completion status of the following clinical trial:

Trial Title: Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe Parkinson's disease (Hoehn and Yahr II/III) diagnosis according to international criteria \[14\],~* History of disturbed nocturnal sleep and presence of EDS (ESS \>10 points),~* Doses of dopaminergic and other PD treatment must have been stable for at least 14 days prior to the screening visit,~* Negative pregnancy test prior to inclusion (except in women who are surgically sterilized/hysterectomized or post-menopausal for longer than 2 years),~* Patients are capable of giving informed consent,~* Signed Informed Consent after being informed.~Exclusion Criteria:~Atypical Parkinson disorder, Parkinson's disease without response to levodopa,~* AHI \>15 or oxygen saturation consistently below 90% on baseline polysomnography~* diagnosis of sleep apnoea-syndrome or COPD~* Severe dementia (MoCA\<22),~* Moderate to severe depression (HADS\>15).~* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,~* Regular use of CNS depressant substances (opioids, barbiturates) as well as melatonin and other sleep-inducing substances,~* Other clinically significant concomitant disease states (e.g., renal insufficiency (creatinin \> 120 resp. GFR \<40ml/min), hepatic dysfunction (GPT \> 100U/l), severe cardiovascular disease, etc),~* Known or suspected non-compliance, substance or alcohol abuse (i.e. \> 0.5 l wine or 1 l beer per day),~* Homeless persons,~* Women who are pregnant or breast feeding,~* Intention to become pregnant during the course of the study,~* Lack of safe contraception, defined as:~Female patients of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.~Please note that female patients who are surgically sterilized/hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential.~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, etc. of the patient,~* Participation in another study with investigational drug within the 30 days preceding and during the present study,~* Previous enrolment into the current study,~* Enrolment of the investigator, his/her family members, employees and other dependent persons,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Oxybate (Type: EXPERIMENTAL): Treatment (500mg Natrii oxybas/ml) will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. The dosage starts at 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night.
- Placebo (Type: PLACEBO_COMPARATOR): Treatment will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. As with the active compound, placebo will be given with a starting dose of 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night.

Based on this trial design, predict the completion outcome and termination type (if applicable).